Priapism Procedures

Priapism is a persistent penile erection (> 4 hours) unrelated to sexual stimulation. The first and most important step is distinguishing ischemic (low-flow, veno-occlusive) priapism — a painful, compartment-syndrome emergency that threatens permanent erectile dysfunction — from non-ischemic (high-flow, arterial) priapism, which is typically painless, traumatic, and not an emergency. Ischemic priapism is by far the commoner type (~95% of presentations), and the chance of recovering erectile function falls steeply with the duration of the episode. Priapism as a condition is covered in the Andrology topic; this page is the procedural reference.

Diagnosis

History and examination usually separate the subtypes — the corpora cavernosa are rigid and (in ischemic disease) tender, while the glans and corpus spongiosum are spared. Corporal blood gas settles indeterminate cases, and color-Doppler ultrasound (patient frog-legged) confirms the subtype and identifies a fistula or arterial injury.

Feature	Ischemic (low-flow)	Non-ischemic (high-flow)
Frequency	Most common (~95%)	Rare
Pain	Painful, rigid, tender corpora	Painless, tumescent but not fully rigid
Cavernous blood	Dark — hypoxic, hypercarbic, acidotic	Bright red — near-arterial
Cause	Non-traumatic (drugs, SCD, malignancy)	Traumatic — cavernous-artery laceration (straddle injury)
Urgency	Emergency	Not emergent

Blood-gas source	PO₂ (mm Hg)	PCO₂ (mm Hg)	pH
Normal arterial	> 90	< 40	7.40
Normal venous	40	50	7.35
Ischemic priapism	< 30	> 60	< 7.25

Time matters: recovery of erectile function after an ischemic episode is ~100% if reversed within 12 hours, ~75% at 12–24 hours, ~50% at 24–36 hours, and approaches 0% beyond 36 hours.

Ischemic Priapism — Management

Ischemic priapism is a urologic emergency — counsel about the risk of ED and penile shortening. Observation, oral agents, and cold packs are not recommended (cold compresses are contraindicated in sickle cell disease).

• First-line — aspiration + intracavernosal phenylephrine (± saline irrigation). Give a penile shaft or dorsal nerve block (lidocaine/bupivacaine without epinephrine) and antibiotics, then aspirate stagnant blood through a 16- or 18-gauge needle placed laterally in the proximal shaft. Phenylephrine (α1-selective, fewest systemic effects) diluted to 100–500 mcg/mL is injected at 100–200 mcg per dose every ≥ 5 minutes for up to 1 hour, to a maximum of ~1000 mcg (1 mg), aspirating before each injection. Monitor blood pressure and heart rate (hypertension, reflex bradycardia, headache, arrhythmia) — a cumulative dose of ~2 mg has caused hypertensive stroke. Aspiration plus a sympathomimetic raises resolution from ~30% to ~80%.
• Sickle cell disease — begin the above without delay and optimise medically in parallel: hematology input, IV hydration, oxygenation, alkalinisation, and exchange transfusion.
• Refractory → surgical shunting. If first-line therapy fails (reasonable after ~1 hour of ineffective treatment), proceed to a shunt; efficacy falls as the corpora grow more acidotic and hypoxic, so move to surgery promptly for episodes ≥ 24 hours. Shunting is generally pursued for episodes ≤ 72 hours.
• > 36 hours or refractory. Options are observation, distal shunting, or an early penile prosthesis (within ~2 weeks) — giving detumescence, pain relief, and preserved length, with infection < 10% (higher if delayed). Gadolinium MRI (or corporal biopsy) at > 36–48 hours assesses cavernosal smooth-muscle viability — non-enhancement signals necrosis/non-viable tissue and favours early prosthesis over further shunting.

Shunt Procedures

When first-line aspiration and sympathomimetic injection fail, a shunt drains the stagnant deoxygenated corporal blood and restores inflow. A bedside percutaneous distal shunt is attempted first; if it fails, an open distal shunt follows. Proximal and vein-anastomotic shunts are now largely historical. Position supine, give antibiotics targeting skin flora (e.g. cefazolin) and local anesthetic with IV/oral analgesia, and place a Foley to identify the urethra.

Percutaneous Distal Shunts (corporoglanular)

• Winter — a large-bore biopsy needle (≥ 18 gauge) is passed through the glans into each distal corpus parallel to the long axis (avoid medial angulation, which injures the urethra), creating multiple tunical windows; bilateral fistulas may be needed for full detumescence. Close skin punctures with figure-of-eight 3-0 chromic if oozing.
• Ebbehoj — the same percutaneous approach with a #11 blade to create larger fistulas, passed multiple times and bilaterally as needed.
• T-shunt — a #10 blade enters the corpus through the glans parallel to the meatus, then is rotated 90° away from the urethra (counter-clockwise on the patient's left, clockwise on the right) to cut a larger T-shaped opening. A tunneling modification passes a 20–24 Fr urethral sound down the corpus to release proximal stagnant blood; the procedure is repeated on the other side.

Open Distal Shunts (corporoglanular)

• Al-Ghorab — under general anesthesia, a 1-cm transverse incision ~1 cm from the dorsal coronal margin exposes the distal corpora (a base tourniquet/Penrose aids visualisation). A ~5-mm conical segment of tunica albuginea is sharply excised from each corpus and dark blood expressed until it changes in colour and character; the corporal defect is left open and skin closed with 3-0 chromic.
• Burnett ("snake" maneuver) — after an Al-Ghorab–type distal window, a 7/8-mm Hegar dilator is passed slightly laterally (away from the urethra) and as proximally as possible into each corpus (frog-leg positioning helps), and stagnant blood is milked out proximal-to-distal; bright oxygenated blood signals restored flow. Cannulation makes it highly effective even in prolonged, refractory episodes, and it may be chosen as the first-line operative option.

Open Proximal and Vein-Anastomotic Shunts (largely historical)

• Quackels (corporospongiosal) — lithotomy, midline perineal incision; a 1-cm corpus-spongiosum window is anastomosed to an adjacent corporotomy with running 5-0 PDS, sparing the urethra to avoid fistula/stricture. The bilateral version (Sacher) staggers the two anastomoses ≥ 1 cm apart to prevent urethral narrowing.
• Grayhack (cavernosaphenous) — the saphenous vein is mobilised, ligated, and tunnelled to an end-to-side anastomosis with the corpus cavernosum (6-0 PDS); postoperative antiplatelet therapy maintains patency.
• Barry (cavernodorsal vein) — the deep or superficial dorsal vein is mobilised and anastomosed end-to-side to the corpus cavernosum (6-0 PDS).

Penile Prosthesis in Acute Priapism

For episodes > 72 hours, long-term ED is almost certain. Placing a prosthesis acutely both treats the priapism and prevents the penile shortening caused by corporal scarring — and avoids the difficult, complication-prone implantation into a densely fibrosed corpus later. Infection and erosion rates are higher than for elective implantation. Evacuate all stagnant blood with copious intracavernosal irrigation; technique otherwise follows standard penile prosthesis placement (penoscrotal or infrapubic) with broad-spectrum prophylaxis.

Recurrent (Stuttering) Priapism

Repeated ischemic episodes — often < 3 hours with intervening detumescence, and strongly tied to sickle cell disease (the commonest cause of priapism in children) — though up to ~30% progress to a major episode. Abort each episode as for acute ischemic priapism, then prevent recurrence:

• Self-injectable phenylephrine — patient-administered intracavernosal α-agonist to abort a developing episode at home.
• Pharmacologic prophylaxis (usually at bedtime) — ketoconazole + prednisone (highest success; monitor LFTs), pseudoephedrine, PDE5 inhibitors, dutasteride/baclofen, and anti-androgens/GnRH agents (which impair fertility and sexual function); in SCD add hydroxyurea and chronic exchange transfusion.
• Penile prosthesis — a definitive option for frequent, refractory disease; place it earlier, before recurrent ischemia causes dense corporal fibrosis.

Non-Ischemic Priapism

High-flow priapism follows a cavernous-artery injury (straddle or pelvic trauma) and is not an emergency: the corpora are tumescent but not fully rigid or painful, and cavernous blood gases resemble arterial blood. Aspiration is only diagnostic.

• First-line: observation — up to ~62% resolve spontaneously (reasonable for ~4 weeks); early ice and perineal pressure may induce vasospasm and thrombose the ruptured artery.
• Second-line: selective arterial embolization — detumescence ~85% with ~80% retaining erectile function; recurrence ~30%, so repeat if it fails. Non-permanent materials (autologous clot) are preferred, as permanent agents carry higher erectile impairment (5% vs 39%), and bilateral embolization raises ED risk.
• Surgical fistula ligation (transcorporal, with intraoperative color-Doppler to localise the site) is reserved for embolization failure. Androgen ablation has significant side effects and is rarely used.

Postoperative Care and Complications

• A Foley is placed for comfort and incision hygiene with a trial of void on the first postoperative day. Apply a light circumferential dressing (e.g. Kerlix) for ~24 hours — avoid over-compression, which worsens ischemia — then a scrotal support with fluff dressing for ~3 days until edema subsides; twice-daily antibiotic ointment until sutures absorb, plus ~1 week of oral skin-flora antibiotics.
• Erectile dysfunction occurs in nearly two-thirds of patients and reflects the ischemic injury itself (worse beyond 24 hours), not the operation; follow with the IIEF and offer a later prosthesis if needed.
• Corporal scarring can cause penile shortening and deformity and makes future prosthesis implantation harder and more complication-prone.
• Urethral injury — blood at the meatus, hematuria, or voiding difficulty warrants urethroscopy; small injuries are managed with a catheter and contrast imaging, larger ones by primary repair.
• Sensory change from nerve injury (reassure; resolution may take months) and thromboembolism with vein shunts (consider peri- and postoperative antiplatelet/anticoagulation).